Company profile
INVENTIVA S.A.
NASDAQ:IVABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LANIFIBRANOR | phase3 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04849728 | phase3 | active_not_recruiting | 2021-08-19 | 2027-09-30 | Inventiva Pharma | A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) |
| NCT03370653 | phase2 | completed | 2017-12-30 | 2019-09-24 | Inventiva Pharma | A Study in MPS VI to Assess Safety and Efficacy of Odiparcil |
| NCT03866369 | phase1 | completed | 2019-01-17 | 2019-08-27 | Inventiva Pharma | Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose |
| NCT03008070 | phase2 | completed | 2017-02-07 | 2020-02-20 | Inventiva Pharma | Phase 2b Study in NASH to Assess IVA337 |
| NCT05232071 | phase2 | completed | 2022-06-29 | 2024-05-08 | Inventiva Pharma | Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
FDA applications (0)
No records yet.